https://www.selleckchem.com/pr....oducts/thymidine.htm
3%-98.3%; NPV, 75.0%-98.7%; ±15-day agreement, 95.6%-97.6%; and median rwOS estimates ranging from 2.8% to 12.7% greater. Sensitivity analysis results (n=17 54 were consistent with the main analysis. Across all cancer types analyzed, this composite mortality variable showed high sensitivity, specificity, PPV, NPV, and ±15-day agreement, and yielded median rwOS values modestly overestimated when compared to NDI-based results. Across all cancer types analyzed, this composite mortality variable showed high sensitivity, specificity, PPV
Like
Comment
Share
